Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of the glycine antagonist, GW468816,
compared with placebo on duration of abstinence and rates of relapse in recently quit female
smokers in a randomized, double-blind, five-week clinical trial.
According to the investigators, the new medication, GW468816, is thought to send certain
signals in the brain that may be effective in helping people stay abstinent after they have
recently quit smoking. GW468816 is a non-nicotine drug.
The investigators of this study hypothesize that subjects receiving GW468816 will demonstrate
a significantly longer time to relapse to smoking than those in the placebo group, as
measured by the primary outcome measure (see below).
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
GlaxoSmithKline Mclean Hospital National Institute on Drug Abuse (NIDA)